News Daily News CMS Greenlights Reimbursement for Renal Denervation Systems L.A. McKeown October 29, 2025
News Daily News Study Supports Cost-effectiveness of Renal Denervation for Hypertension Todd Neale August 23, 2024
News Daily News Statins Effective For Primary Prevention in Old and Very Old Michael O'Riordan May 29, 2024
News Daily News Holistic Screening for Preeclampsia in First Trimester Bests Clinical Factors Alone Caitlin E. Cox May 20, 2024
News Daily News Symplicity Spyral Approved: FDA Clears Second Renal Denervation System Todd Neale November 20, 2023
News Daily News FDA Approves Paradise Renal Denervation System: What Comes Next? Todd Neale November 08, 2023
News Daily News Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel L.A. McKeown August 23, 2023
News Daily News ReCor’s Renal Denervation System Gets Thumbs Up From FDA Advisory Panel L.A. McKeown August 22, 2023
News Daily News As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions L.A. McKeown August 18, 2023
News Daily News European Societies Define Best Practices for Performing Renal Denervation Todd Neale February 21, 2023
News Daily News BP Reduction With Renal Denervation Still Evident a Decade On Michael O'Riordan January 31, 2023
News Daily News Reduction in BP Drives Treatment Preference for Hypertensive Patients Michael O'Riordan December 20, 2022
News Daily News RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation Todd Neale July 26, 2022
News Daily News Higher Subclinical Atherosclerosis in Black Americans Remains Unexplained Yael L. Maxwell July 15, 2022
News Daily News CAC Tests Boost CAD Prediction in Younger Patients at Risk for ASCVD Yael L. Maxwell October 14, 2021
News Daily News Renal Denervation a Third Option for Hypertension, European Experts Say Todd Neale September 17, 2021
News Daily News ‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues Todd Neale June 24, 2019
News Daily News Renal Denervation Lowers BP in Sham-Controlled Studies: Meta-Analysis Michael O'Riordan April 02, 2019